MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced certain preliminary, unaudited results for the quarter ended June 30, 2024, and updated full year 2024 revenue outlook. The company plans to report its complete results and host its earnings conference call for the second quarter of 202 ...

Preliminary, Unaudited Second Quarter Revenue Updated Full Year 2024 Revenue Guidance "We are so proud of our team's strong execution and revenue performance in the second quarter, which showed sequential revenue growth acceleration in the U.S.," said Tim Herbert, Chairman and CEO of Inspire. "With the strong momentum we are seeing in our business, we have increased confidence regarding strong continued revenue growth in the second half of 2024. As a result, we are increasing our revenue guidance to $788 mi ...

Stryker, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 10.6%. SYK's earnings surpassed estimates in each of the trailing four quarters, with the average being 4.9%. Stryker has gained 17.3% against the industry's 2.9% decline in the past year. Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.5%. BSX's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.5%. Boston S ...

MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today the addition of Melissa J. Mann as Chief People Officer, effective July 22, 2024. Ms. Mann has over 25 years experience in human capital management and joins Inspire from UnitedHealth Group where she served for 8 years in its Optu ...

MINNEAPOLIS, July 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced CE mark certification under the European Union's Medical Device Regulation (EU MDR 2017/745) for Inspire therapy. "Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, ...

MINNEAPOLIS, July 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that the European Union Medical Device Regulation (EU MDR) has approved additional magnetic resonance imaging (MRI) scan conditions for use with Inspire therapy. This full-body MRI approval expands the Inspire use labeling t ...

"Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, with uninterrupted CE mark approval since 2010," said Tim Herbert, Chairman and President of Inspire. "The Inspire team has worked diligently with our notified body in Europe to complete the review process, which included obtaining temporary approval through derogation authorization to continue to deliver Inspire product in several countries." There are two changes to Inspire therapy that are now ...

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Inspire Medical Systems, Inc. (NYSE: INSP) on behalf of long-term stockholders following a class action complaint that was filed against Inspire Medical on December 22, 2023 with a Class Period from May 3, 2023 to November 7, 2023. Our investigation concerns whether the board of directors of Inspire Medical have breached their fiduciary dutie ...

Inspire Medical Systems Inc. (INSP) has issued a recall of its Inspire IV Implantable Pulse Generator (IPG) Model 3028 due to a critical manufacturing defect. The FDA has classified this as the most serious type of recall, as the defect can lead to electrical leakage in the sensing circuit post-implantation. This leakage can cause system malfunctions, potentially resulting in severe health consequences, including inconsistent stimulation, painful shocks or even death. There may be an urgent need for revisio ...

There have been no reported injuries. There have been no reports of death. The IPG works with external programmers that allow the physician to set and adjust the therapy parameters and the patient to control the therapy's activation and intensity. Loading... The FDA has labeled a recall of Inspire Medical Systems, Inc.'s INSP nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire Medical Systems is recalling Inspire IV Implantable Pulse Generator (IPG) Model 3028 du ...